Assessment of 111In-Ibritumomab pretreatment imaging in 90Y-Ibritumomab radioimmunotherapy for relapsed or refractory low-grade B cell lymphoma.

被引：0
|
作者：
Kaneko, K. [1 ]
Uike, N. [1 ]
Shinozaki, K. [1 ]
Choi, I. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [31] Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
    Storto, G.
    Nardelli, A.
    Pellegrino, T.
    Perna, F.
    De Falco, T.
    Erra, P.
    Ortosecco, G.
    Castaldi, E.
    Speranza, A.
    Klain, M.
    De Renzo, A.
    di Nuzzo, C.
    Pace, L.
    Rotoli, B.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [32] Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma
    Witzig, TE
    White, CA
    Gordon, LI
    Wiseman, GA
    Emmanouilides, C
    Murray, JL
    Lister, J
    Multani, PS
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1263 - 1270
  • [33] Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y-ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy (RIT).
    Jurczak, W
    Giza, A
    Krochmalczyk, D
    Wegrzyn, J
    Hubalewska-Dydejczyk, A
    Sowa-Staszczak, A
    Knopinska-Posluszny, W
    Zdziarska, B
    Kyrcz-Krzemien, S
    Boguradzki, P
    Poplawska, L
    Skotnicki, A
    BLOOD, 2005, 106 (11) : 690A - 690A
  • [34] Cost of 90Y-ibritumomab tiuxetan radioimmunotherapy versus cost of standard regimens for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma in Switzerland
    Frei, Andreas
    Delmore, Geoffrey
    Hitz, Felicitas
    Schwenkglenks, Matthias
    Szucs, Thomas
    BLOOD, 2007, 110 (11) : 975A - 975A
  • [35] FDG-PET/CT Early After 90Y-Ibritumomab Tiuxetan Therapy Predicts Outcome in Relapsed or Refractory Indolent B-Cell Lymphoma
    Okada, Masaya
    Fujimori, Yoshihiro
    Oku, Naohiko
    Tamekane, Akira
    Takafuta, Toshiro
    Nakajima, Toshiyuki
    Tokugawa, Tazuko
    Sawada, Akihiro
    Ishii, Shin-ichi
    Kaida, Katsuji
    Ikegame, Kazuhiro
    Soma, Toshihiro
    Ogawa, Hiroyasu
    BLOOD, 2012, 120 (21)
  • [36] Experience on Therapy with 90Y Ibritumomab Tiuxetan in Relapsed/Refractory Non-Hodgkin Lymphoma. Analysis of Outcomes
    Baringo, T.
    Giraldo, P.
    Lievano, P.
    Navarro, P.
    Arroyo, E.
    Ananos, M.
    de la Cueva, L.
    Abos, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S352 - S352
  • [37] Radioimmunotherapy with 90Y ibritumomab tiuxetan in refractory/relapsed follicular non-hodgkin lymphoma results in an Spanish center
    Rubio-Martinez, A.
    Agustin, M. J.
    Recasens, V.
    Lopez-Gomez, L.
    Perella, M.
    Perez-Lungmus, G.
    Baringo, T.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 418 - 418
  • [38] Efficacy of radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan (zevalin) for the treatment of relapsed or resistant aggressive lymphoma heavily pretreated with rituximab plus chemotherapy
    Botto, B.
    Bello, M.
    Benevolo, G.
    Cabras, M. G.
    Castellino, C.
    Chiappella, A.
    Fioritoni, G.
    Freilone, R.
    Martelli, M.
    Orsucci, L.
    Pregno, F.
    Scapoli, F.
    Tonso, A.
    Bisi, G.
    Vitolo, U.
    Gallo, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 64 - 65
  • [39] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) is a safe and effective treatment option for older patients with relapsed or refractory low-grade non-Hodgkin's lymphoma (NHL)
    Meredith, R
    Schilder, RJ
    Emmanouilides, C
    Vo, K
    Witzig, TE
    Flinn, IW
    Darif, M
    Gordon, LI
    Molina, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S421 - S421
  • [40] 131I-Tositumomab (Bexxar®) vs.90Y-Ibritumomab (Zevalin®) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma
    Andrei Iagaru
    Erik S. Mittra
    Kristen Ganjoo
    Susan J. Knox
    Michael L. Goris
    Molecular Imaging and Biology, 2010, 12 : 198 - 203
12345